Does broad IgG/IgA reactivity to microbial and neuronal antigens prove active infection or a specific autoimmune neurologic disorder?

Broad IgG/IgA reactivity is best interpreted as a contextual serologic pattern rather than proof of multiple active infections or a defined neurologic autoimmune syndrome. In a 77-year-old man, interpretation should be anchored to symptoms, examination, disease-specific pretest probability, and orthogonal testing rather than the breadth of antibody positivity alone.

Microbial seroreactivity

• Pathogen-specific IgG commonly persists for years or lifelong after infection or vaccination; IgA may persist for months and can be less specific. A broad panel can therefore represent accumulated prior exposures rather than concurrent infection.
• Polyclonal B-cell activation can generate polyreactive antibodies and multiple apparent pathogen-positive serologies without true coinfection. Assay cross-reactivity or nonspecific immunoassay reactivity can also contribute, with importance varying by pathogen and assay platform.
• Active infection is more convincingly supported by direct detection from the relevant symptomatic site—NAAT/PCR, culture, or antigen testing—than by antibody reactivity alone. If direct testing is unavailable, seroconversion or a significant paired-sample IgG increase, commonly a fourfold rise between acute and convalescent sera, supports recent infection; stable titers favor remote exposure.

Neuronal antibody findings

• Broad neuronal IgG/IgA reactivity alone should not be used to assign a single autoimmune neurologic diagnosis. Polyclonal activation and analytic cross-reactivity are plausible contributors, particularly for weak, isolated, or clinically discordant serum results.
• Diagnostic significance depends on a syndrome-concordant phenotype and corroboration with MRI, EEG, CSF, and independent confirmatory antibody testing. CSF-confirmed, phenotype-matched findings carry substantially greater specificity than serum-only reactivity.

Bottom line

• Broad microbial and neuronal antibody positivity warrants targeted clinical correlation and confirmation, not automatic attribution to active infection or one specific autoimmune neurologic disorder.